PMID- 11001068 OWN - NLM STAT- MEDLINE DCOM- 20001019 LR - 20240109 IS - 0028-0836 (Print) IS - 0028-0836 (Linking) VI - 407 IP - 6801 DP - 2000 Sep 14 TI - Angiogenesis in cancer and other diseases. PG - 249-57 AB - Pathological angiogenesis is a hallmark of cancer and various ischaemic and inflammatory diseases. Concentrated efforts in this area of research are leading to the discovery of a growing number of pro- and anti-angiogenic molecules, some of which are already in clinical trials. The complex interactions among these molecules and how they affect vascular structure and function in different environments are now beginning to be elucidated. This integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases. But owing to several unanswered questions, caution is needed. FAU - Carmeliet, P AU - Carmeliet P AD - The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium. peter.carmeliet@med.kuleuven.ac.be FAU - Jain, R K AU - Jain RK LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PT - Review PL - England TA - Nature JT - Nature JID - 0410462 RN - 0 (Endothelial Growth Factors) RN - 0 (Lymphokines) RN - 0 (Vascular Endothelial Growth Factor A) RN - 0 (Vascular Endothelial Growth Factors) SB - IM MH - Animals MH - Disease MH - Endothelial Growth Factors/physiology MH - Humans MH - Lymphokines/physiology MH - Neoplasms/*blood supply/genetics MH - *Neovascularization, Pathologic/drug therapy/genetics MH - Vascular Endothelial Growth Factor A MH - Vascular Endothelial Growth Factors RF - 75 EDAT- 2000/09/23 11:00 MHDA- 2000/10/21 11:01 CRDT- 2000/09/23 11:00 PHST- 2000/09/23 11:00 [pubmed] PHST- 2000/10/21 11:01 [medline] PHST- 2000/09/23 11:00 [entrez] AID - 10.1038/35025220 [doi] PST - ppublish SO - Nature. 2000 Sep 14;407(6801):249-57. doi: 10.1038/35025220.